Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Old drugs for a new bug: influenza, HIV drugs enlisted to fight SARS

Article Abstract:

Researchers and pharmaceutical companies are racing to develop effective drugs against SARS in case the infection re-emerges in the spring of 2004. They are looking at protease inhibitors and interferon, which were both developed to treat viral infections such as AIDS and hepatitis. Some antiviral agents developed for influenza may be useful for treating SARS. A new class of drugs call fusion inhibitors is also being tested.

Author: Vastag, Brian
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2003
Antiviral agents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


CDC unveils SARS plan: emphasizes rapid identification, communication. (Centers for Disease Control and Prevention, severe acute respiratory syndrome)

Article Abstract:

The US Centers for Disease Control and Prevention has developed a plan for dealing with SARS in the event of an outbreak in the US. There is no effective vaccine or treatment for SARS, so patients must be quickly isolated and those exposed to them must be quarantined. Communities may even consider closing schools and other public gatherings. The report is available on the CDC's web site.

Author: Vastag, Brian
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2003
Administration of Public Health Programs, Centers for Disease Control, Reports, United States. Centers for Disease Control and Prevention

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Experimental drugs take aim at obesity

Article Abstract:

Only two drugs for treating obesity are available as of 2003 and two more are being tested. Xenical and Meridia have different mechanisms and side effects. Axokine and rimonabant are under development and are being tested in phase 3 trials as of April, 2003.

Author: Vastag, Brian
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2003
Obesity, Weight reducing preparations, Anti-obesity agents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Product development, Drug therapy, Severe acute respiratory syndrome
Similar abstracts:
  • Abstracts: Zidovudine now or later? Generic HIV drugs - enlightened policy for global health. Antiretroviral therapy where resources are limited
  • Abstracts: Rx: Canadian drugs. Experts look for ways to lessen impact of drug shortages and discontinuations
  • Abstracts: Vaginal birth after cesarean section: the impact of patient resistance to a trial of labor. Perinatal outcomes in preeclampsia that is complicated by massive proteinuria
  • Abstracts: Ovulation induction/intrauterine insemination in infertile couples is associated with low-birth-weight infants
  • Abstracts: Changes in the isoforms of the sodium pump in the placenta and myometrium of women in labor. Maternal and transplacental pharmacokinetics of azithromycin
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2026 Advameg, Inc.